Bristol Myers Squibb stock reacts to latest Opdivo data and solid 2024 outlook

Bristol Myers Squibb stock sits in the large-cap global pharma segment as Bristol-Myers Squibb Company (ISIN US0897961004) continues to lean on oncology and immunology growth, backed by multibillion-dollar drugs and detailed 2024 guidance from its latest financial updates. In its most recent full-year report for 2023, the company highlighted double-digit contributions from its new product portfolio and set out quantitative expectations for 2024 revenue and earnings, giving investors a clearer framework for valuing the stock.

Revenue above USD 45 billion and new product momentum

According to the company’s 2023 annual reporting and investor presentation, Bristol Myers Squibb generated total revenue of around $45.0 billion in 2023, with its newest product portfolio contributing roughly $3.6 billion for the year as the group continued to diversify beyond older blockbusters. The same materials show that the new product portfolio was expected to exceed $3.0 billion of revenue already in 2023, so the reported figure of about $3.6 billion reflects an outperformance versus that initial threshold and underlines how newer launches are scaling in the market.

Management also emphasized in that 2023 disclosure that so-called inline and new product portfolio brands together were targeting a path toward at least $8.0 billion of additional risk-adjusted sales growth through the mid-2020s. This growth ambition sits beside a disciplined cost structure, with the 2023 report noting that the company maintained a high gross margin level typical for innovative pharmaceuticals while continuing to allocate several billion dollars annually to research and development to support its pipeline.

On the profitability side, Bristol Myers Squibb reported in its 2023 filings that GAAP diluted earnings per share were materially influenced by charges related to acquisitions and intangible asset write-downs, whereas non-GAAP diluted EPS was presented to illustrate underlying earnings power. For 2023, non-GAAP diluted EPS was reported in the high single-digit dollar range per share, and the company set a 2024 non-GAAP EPS guidance corridor that pointed to continued strong cash generation, underpinning dividends and capital return.

Opdivo and Eliquis remain multibillion-dollar pillars

Within that 2023 performance, Bristol Myers Squibb’s oncology and cardiovascular franchises were central. The annual report and associated investor materials show that the cancer immunotherapy Opdivo delivered revenue of roughly $9.0 billion in 2023, supported by uptake in multiple tumor types and combination regimens. In earlier years, Opdivo revenue had been several billion dollars lower, so reaching a figure around $9.0 billion underscores how the brand has expanded its indications and penetration over time.

The anticoagulant Eliquis, co-marketed with a partner, remained even larger. Company figures for 2023 indicate that Eliquis generated revenue in the low- to mid-teens of billions of dollars for Bristol Myers Squibb’s share, after having already crossed the $10.0 billion mark in prior years. This progression from roughly $10.0 billion in earlier periods to well over that level in 2023 illustrates Eliquis’s sustained global adoption for stroke prevention in atrial fibrillation and treatment of venous thromboembolism, despite the looming impact of generic competition later in the decade.

Beyond these two anchors, Bristol Myers Squibb has been scaling newer brands such as the multiple myeloma therapy Abecma and the anemia drug Reblozyl. Company reporting for 2023 pointed to Reblozyl revenue in the several-hundred-million-dollar range, with growth versus 2022 running at a strong double-digit percentage rate as additional indications and geographies were brought on line. These expansion dynamics in newer brands form part of the company’s articulated plan to offset patent cliffs in its older portfolio.

Cash flow, capital returns, and 2024 guidance metrics

Bristol Myers Squibb’s 2023 cash flow figures support this strategic repositioning. In its annual filings and investor presentations, the company reported operating cash flow comfortably above $10.0 billion for 2023, giving the group funds to invest in research, acquisitions, and shareholder returns. Against that backdrop, Bristol Myers Squibb returned several billion dollars to shareholders via dividends and share repurchases in 2023, while at the same time funding pipeline acquisitions and internal development programs.

For 2024, the company’s most recent guidance update referenced in its investor materials described expected total revenue in a corridor around the 2023 level, with modest growth helped by the new product portfolio. The same guidance indicated a non-GAAP diluted EPS range in the mid- to high-single-digit dollars per share, reflecting management’s view that growth in new products and cost discipline would support earnings even as major brands like Revlimid face generic erosion. This quantified guidance range provides investors with a concrete benchmark when modeling potential scenarios for Bristol Myers Squibb stock.

The company also noted in its 2024 outlook that research and development spending would remain a significant percentage of sales, consistent with its innovation-led strategy. In 2023, R&D expenses ran into the high single-digit billions of dollars, and a similar magnitude was indicated for 2024, underlining management’s willingness to reinvest a substantial share of cash flow into advancing its oncology, hematology, immunology, and cardiovascular pipelines.

Opdivo immunotherapy and its market role

Opdivo, Bristol Myers Squibb’s flagship programmed death-1 (PD-1) immune checkpoint inhibitor, plays a key role in the company’s oncology strategy. The 2023 annual report and oncology portfolio summaries describe how Opdivo has secured approvals across a range of cancers, including non-small cell lung cancer, melanoma, renal cell carcinoma, and several others. This broad label, often in combination regimens, helps explain why Opdivo revenue climbed to around $9.0 billion in 2023 from materially lower levels only a few years earlier.

Recent clinical developments, highlighted on the company’s oncology pipeline pages and in updates presented at major oncology conferences, show that Bristol Myers Squibb continues to generate new data for Opdivo-based combinations. These updates typically focus on progression-free survival, overall survival, and safety results in new tumor types or lines of therapy. While individual trial outcomes can influence sentiment toward Bristol Myers Squibb stock, the overall direction has been to reinforce Opdivo’s position as a foundational immunotherapy brand within the company’s portfolio.

Beyond Opdivo, Bristol Myers Squibb actively advances other oncology assets such as the antibody-drug conjugate candidates and cell therapies. The company’s cell therapy segment, which includes CAR T products like Abecma and Breyanzi, delivered several hundred million dollars of revenue in 2023 with rapid percentage growth versus 2022 from a smaller base. Management commentary frames these therapies as important contributors to long-term growth, complementing the more mature Opdivo and Eliquis franchises.

Bristol Myers Squibb stock and valuation backdrop

Bristol Myers Squibb stock is listed on the New York Stock Exchange under the ticker BMY and is part of major U.S. equity indices that track large-cap healthcare companies. Market data from leading financial portals show that the company’s market capitalization stands in the tens of billions of dollars, placing it among the larger global biopharmaceutical groups. Over the past twelve months, the stock’s price has typically traded within a range that reflects ongoing debate over patent expiries versus the value of its pipeline and new products.

For investors, key valuation metrics such as the price-to-earnings ratio on a non-GAAP basis and the dividend yield help frame Bristol Myers Squibb stock against peers. Based on recent non-GAAP EPS figures in the high single-digit dollars and a share price in the tens of dollars, the resulting P/E multiple has often been below that of some faster-growing biotech names, a gap that some market participants attribute to concerns about the pace at which new products can replace revenue from brands facing loss of exclusivity.

At the same time, Bristol Myers Squibb’s dividend represents an important component of total shareholder return. Company disclosures indicate that the annual dividend per share has been increased periodically in recent years, supported by robust cash flow. The combination of a dividend yield that is competitive with the broader market and ongoing share repurchases means that capital returns are a central feature of the investment case, even as the company commits substantial resources to its development pipeline.

Fact box: Bristol Myers Squibb at a glance